European Union
Leqembi (Lecanemab) Marks a Breakthrough in Alzheimer's Treatment with Launch in the EU
The launch of Leqembi (lecanemab) in the EU marks a significant milestone in the treatment of Alzheimer's disease, as it is the first therapy to target an underlying cause of the condition. Leqembi received European Commission approval in April 2025 for the treatment of adult patients with mild